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Original Article
Safety of anticoagulation with uninterrupted warfarin vs. 
interrupted dabigatran in patients requiring an implantable 
cardiac device
Shivanshu Madan1, Purushothaman Muthusamy2, Katie L. Mowers3, Darryl A. Elmouchi4, Bohuslav 
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Background: The optimal strategy of peri-procedural anticoagulation in patients undergoing permanent 
cardiac device implantation is controversial. Our objective was to compare the major bleeding and 
thromboembolic complications in patients managed with uninterrupted warfarin (UW) vs. interrupted 
dabigatran (ID) during permanent pacemaker (PPM) or implantable cardioverter defibrillators (ICD) 
implantation.
Methods: A retrospective cohort study of all eligible patients from July 2011 through January 2012 was 
performed. UW was defined as patients who had maintained a therapeutic international normalized ratio 
(INR) on the day of the procedure. ID was defined as stopping dabigatran ≥12 hours prior to the procedure 
and then resuming after implantation. Major bleeding events included hemothorax, hemopericardium, 
intracranial hemorrhage, gastrointestinal bleed, epistaxis, or pocket hematoma requiring surgical 
intervention. Thromboembolic complications included stroke, transient ischemic attack, deep venous 
thrombosis, pulmonary embolism, or arterial embolism.
Results: Of the 133 patients (73.4±11.0 years; 91 males) in the study, 86 received UW and 47 received ID. 
One (1.2%) patient in the UW group sustained hemopericardium perioperatively and died. In comparison, 
the ID patients had no complications. As compared to the ID group, the UW group had a higher median 
CHADS2 score (2 vs. 3, P=0.04) and incidence of Grade 1 pocket hematoma (0% vs. 7%, P=0.09). Neither 
group developed any thromboembolic complications.
Conclusions: Major bleeding rates were similar among UW and ID groups. Perioperative ID appears to be 
a safe anticoagulation strategy for patients undergoing PPM or ICD implantation.
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Submitted Aug 26, 2015. Accepted for publication Sep 25, 2015.
doi: 10.3978/j.issn.2223-3652.2015.10.06
View this article at: http://dx.doi.org/10.3978/j.issn.2223-3652.2015.10.06
4 Madan et al. Warfarin vs. dabigatran in implantable cardiac devices
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2016;6(1):3-9www.thecdt.org
Introduction
Approximately 176,000 patients receive permanent 
pacemakers (PPM) or implantable cardioverter defibrillators 
(ICD) annually in the USA (1). Of these, a significant 
proportion receive chronic oral anticoagulation therapy 
with warfarin for treatment of atrial fibrillation (2). As 
such, an understanding of appropriate management of 
anticoagulation in the context of device implantation is 
crucial (3,4). Unfortunately, agreement on an optimal 
perioperative strategy remains controversial.
In the last decade, various anticoagulation regimens 
have been employed and respective outcomes compared 
(3-8). Approaches are classified as either “interrupted” or 
“continued” anticoagulation. Interrupted anticoagulation 
places patients at higher risk for cardioembolic events, 
but continued therapy may increase the risk of bleeding 
complications such as pocket hematomas (5,6). A previously 
proposed method based on ACC/AHA guidelines of 
interrupted warfarin therapy with low molecular weight 
heparin (LMWH) bridging has been abandoned in many 
centers due to a concomitant high incidence of pocket 
hematomas (6-9). Instead, uninterrupted warfarin (UW) 
has become an accepted strategy as it has been linked to 
reduced rates of bleeding complications and shorter hospital 
stays (5,10-13).
However, the availability of newer anticoagulants such 
as dabigatran brings the possibility of superior outcomes 
for this patient population. The more predictable 
pharmacological profiles of these new drugs allow for short-
term interruption that may potentially improve device 
implantation safety by reducing bleeding complications. 
Additionally, the ability to stop these drugs for a short 
period of time before clot formation can occur may lead to 
similar efficacy in regards to prevention of thromboembolic 
adverse outcomes in high risk patients.  However, 
certain agents such as LMWH with short half-lives have 
been linked to increased risk of pocket hematoma 
development (4). This immediate post-operative risk 
of increased bleeding is not as well-known with newer 
anticoagulants such as dabigatran.
The RE-LY trial demonstrated superior efficacy of 
dabigatran in the prevention of stroke and systemic 
embolism, as well as similar rates of major bleeding when 
compared to warfarin (14). There are few articles regarding 
safety of perioperative anticoagulation with dabigatran 
(15-18). In this retrospective study, we compared the safety 
of UW to interrupted dabigatran (ID) in patients requiring 
a PPM or ICD. We hypothesized that the risk of major 
bleeding would be similar between UW and ID therapy and 
the use of perioperative dabigatran in patients undergoing 
device implantation would be a safe strategy.
Material and methods
Study design
This was a single center retrospective study comparing 
major bleeding and thromboembolic events in patients who 
underwent PPM or ICD placement with either UW or ID 
therapy during a six-month period, July 2011 to January 
2012, at Spectrum Health—Butterworth Hospital, a 989-bed 
teaching hospital in West Michigan. Five experienced 
cardiac electrophysiologists, who implant approximately 
1,250 devices each year, performed all procedures. Patient 
charts were reviewed systematically to obtain demographic, 
clinical, and laboratory characteristics pre- and post-
procedure. The study was approved by the hospital 
institutional review board.
Inclusion/exclusion criteria
All patients who required a new device implantation or had 
an existing device replaced and met the inclusion criteria 
were included. Inclusion criteria included documented 
diagnosis of atrial fibrillation and currently on chronic 
anticoagulation with either warfarin or dabigatran. The 
exclusion criteria included age <18 years, pregnancy, 
history of mechanical heart valves, international normalized 
ratio (INR) >4 and patients who switched therapy from 
dabigatran to warfarin or vice versa in the perioperative 
time period.
Clinical procedures
Perioperative anticoagulation protocols were based 
on the clinical judgment of the attending cardiac 
electrophysiologist. If a patient was in the UW cohort, 
INR was checked the morning of the procedure to confirm 
that the INR was <4. All patients in the ID group had non-
valvular atrial fibrillation, as well as a creatinine clearance 
greater than 30 mL/min and had dabigatran held at least 
12 hours prior to the procedure. Patients received a dose 
of dabigatran at a mean time of 23.3 hours (range, 12-
91 hours) prior to the start of procedure and resumed 
dosing at a mean time of 21.0 hours (range, 9-54 hours) 
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after the procedure. PPM and ICD leads were placed under 
fluoroscopic guidance. Leads were implanted through 
the subclavian or axillary vein after administration of 
prophylactic antibiotic and local anesthesia. Both active and 
passive fixation leads were used for atrial and ventricular 
leads.
Outcome variables and definitions
The primary outcome of the study was major bleeding 
within one-month post procedure. Major bleeding was 
defined as hemothorax, hemopericardium, intracranial 
hemorrhage, gastrointestinal bleed, epistaxis, or pocket 
hematoma requiring surgical intervention. Pocket 
hematoma was defined as a palpable and visible soft mass 
in the pacemaker pocket with or without the need for 
evacuation. Pocket hematomas were graded 0 to 3 based 
on severity. A pocket hematoma score of 0 described either 
skin ecchymosis or minimal hematoma, whereas a score of 
3 described a hematoma that required surgical evacuation. 
Scores of 1 and 2 correlated to a hematoma size smaller 
than or greater than the size of the generator, respectively. 
All patients were followed up within 1-2 weeks post-procedure 
for surgical site assessment in the electrophysiology 
outpatient clinic or in the hospital. Thromboembolic 
complications included stroke, transient ischemic attack, 
deep venous thrombosis, pulmonary embolism, or arterial 
embolism. All-cause mortality within 1-month post-
procedure was obtained from patient charts and verified 
using the social security death index.
Statistical analysis
Summary statistics were calculated. Continuous variables 
are expressed as the mean ± SD, categorical data as 
percentages, and the CHADS2 data as the median (range). 
Differences among quantitative variables for the two groups 
were determined using the t-test. Categorical variables were 
analyzed using the Fisher’s Exact test. CHADS2 data were 
compared using the Mann-Whitney test. Significance was 
assessed at P<0.05. Statistical analyses were performed using 
IBM SPSS Statistics version 20 (Armonk, NY, USA).
Results
A total of 133 patients met the inclusion criteria resulting 
in 86 (64.7%) in the UW cohort and 47 (35.3%) in the 
ID cohort. Baseline characteristics are shown in Table 1. 
The mean age of the sample was 73 years and the majority 
of patients were males. Patients in the UW group had 
significantly higher median CHADS2 scores than the ID 
group. Notably, the prevalence of prior stroke or TIA was 
over two-fold higher in the UW group than in the ID 
cohort, although this was not a significant difference. With 
regards to the other comorbidities, there were no significant 
differences between the groups. Of note, mean INR on the 
day of procedure in the UW group was 2.3±0.7 (Table 1).
Overall, 71 patients (53.4%) received a PPM while 
62 (46.6%) had ICD placed. Among the UW cohort, 45 
(52.3%) received a PPM and 41 (47.7%) received an ICD. 
Of those patients who received an ICD in UW group, 23 
(26.7%) had biventricular ICD. In the ID group, 26 (55.3%) 
received a PPM and 21 (44.7%) received an ICD. Fourteen 
patients (29.8%) in the ID cohort received biventricular 
ICDs. Indications for implantation of the device are shown 
in Table 2.
Among the 133 patients included in the study, there was 
one major bleeding event, which occurred in the UW group 
(Table 3). This was also the only patient who died within 
one month of the procedure. The incidence of pocket 
hematomas was higher in the UW group (7%) than in the 
ID group (0%), but this was not statistically significant 
(P=0.09). All pocket hematomas were identified as grade 1 
and none required surgical evacuation or anticoagulation 
cessation. Overall, there was no statistically significant 
difference in thromboembolism and bleeding between the 
UW and ID cohorts.
Discussion
This study suggests that dabigatran use perioperatively 
in patients requiring a PPM or ICD when compared to 
continued anticoagulation with warfarin may lead to less 
bleeding complications. Previous studies have demonstrated 
a higher incidence of hemorrhagic events associated with 
heparin bridging without warfarin reversal (19,20). A higher 
incidence of hemorrhage associated with post-operative use 
of heparin has also been described in the literature (6,7,21). 
Cheng et al. showed that LMWH used post-operatively 
causes an increased incidence of pocket hematoma (4). 
Continued anticoagulation with UW has been shown to be 
safer than heparin bridging in prior studies (5,10-13).
To date, few studies have investigated the safety and 
efficacy of dabigatran in the perioperative period. Rowley 
et al. performed a prospective observational study of 
patients receiving dabigatran but only included 25 patients 
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Table 1 Patient baseline characteristics
Characteristic All patients [n=133] Uninterrupted warfarin [n=86] ICD [n=47] P value
Age (years)* 73.4±11.0 73.0±11.6 74.0±9.7 0.63
Gender—male 68.4% [91] 67.4% [58] 70.2% [33] 0.85
Race—caucasians 97% [129] 95.3% [82] 100% [47] 0.30
BMI (kg/m2)* 29.2±6.2 28.9±6.1 29.8±6.5 0.46
CHADS2 score^ 3 [0-6] 3 [1-6] 2 [0-5] 0.004
Stroke/TIA 21.1% [28] 25.6% [22] 12.8% [6] 0.12
Hypertension 80.5% [107] 82.6% [71] 76.6% [36] 0.49
CAD 51.9% [69] 55.8% [48] 44.7% [21] 0.28
DM 30.8% [41] 30.2% [26] 31.9% [15] 0.85
PE 3% [4] 4.7% [4] 0% [0] 0.30
DVT 6.8% [9] 9.3% [8] 2.1% [1] 0.16
Epistaxis 0% [0] 0% [0] 0% [0] >0.999
Aspirin use 51.1% [68] 52.3% [45] 48.9% [23] 0.72
Clopidogrel use 4.5% [6] 3.5% [3] 6.4% [3] 0.67
Previous PPM/ICD 31.6% [42] 34.9% [30] 25.5% [12] 0.33
Ejection fraction (%)* 40.7±16.7 39.3±17.0 44.1±15.7 0.11
Hemoglobin* 13.2±1.8 13.0±1.8 13.6±5.4 0.33
Creatinine* 1.2±0.6 1.3±0.8 1.1±0.3 0.14
GFR* 48.5±13.6 47.3±14.0 51.0±12.9 0.13
INR*
@ Procedure 2.3±0.7
@ 1 Week 2.5±0.7
@ Complication 2.8±0.8    
*, Data are shown as means±SD; ^, data are shown as median (range). The CHADS2 score is a measure of the risk of stroke in 
which congestive heart failure, hypertension, an age of 75 years or older, and diabetes mellitus are each assigned 1 point and 
previous stroke or transient ischemic attack is assigned 2 points; the score is calculated by summing all points for a given patient. 
CAD, coronary artery disease; DM, diabetes mellitus; PE, pulmonary embolism; DVT, deep vein thrombosis; PPM, permanent 
pacemaker; ICD, implantable cardioverter defibrillators; BUN, blood urea nitrogen; GFR, glomerular filtration rate; TIA, transient 
ischemic attack.
Table 2 Indications for device implantation
Characteristic All patients [%] [n=133] Uninterrupted warfarin [%] [n=86] Interrupted dabigatran [%] [n=47]
Indication
Bradycardia 18 [24] 12.8 [11] 27.7 [13]
Slow atrial fibrillation 6 [8] 7 [6] 4.3 [2]
RFA/permanent pacing 19.5 [26] 20.9 [18] 17 [8]
VT/VF 9 [12] 10.5 [9] 6.4 [3]
CHF req. biventricular device 40.6 [54] 41.9 [36] 38.3 [18]
Mobitz type 2 AV block 3.0 [4] 3.5 [3] 2.1 [1]
Type 3 AV block 3.8 [5] 3.5 [3] 4.3 [2]
AV, atrioventricular; CHF, congestive heart failure; RFA, radiofrequency ablation with permanent pacing; VF, ventricular fibrillation; 
VT, ventricular tachycardia.
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in their investigation (15). In concordance with results from 
this study, there was no significant increase of thrombosis 
or major bleeding complications. Healey et al. performed 
a retrospective analysis of 4,591 patients from the RE-LY 
study undergoing various invasive procedures who were 
receiving anticoagulation therapy with either warfarin or 
dabigatran (22). There was no significant difference in rates 
of periprocedural major bleeding in various dabigatran 
cohorts compared to warfarin. However, there was a large 
range in dosing time of dabigatran pre- and post-procedure.
Similarly, we found no significant differences in major 
bleeding events between the ID and UW groups in our 
study. Patients in the UW group were associated with a 
statistically non-significant trend towards increased pocket 
hematoma formation compared to the ID cohort. This 
is an interesting finding since an increased risk of pocket 
hematoma development has been linked to the use of 
agents with short half-lives in prior studies when compared 
to an UW strategy. Incidence of pocket hematoma while 
on an UW strategy in this study was consistent with a 
previous well-constructed small randomized trial (23). The 
increased bleeding trends in pocket hematomas in the UW 
may be due to the fact that patients are no longer fully 
anticoagulated at the time of implant in the ID group but 
remain therapeutically anticoagulated in the UW group. 
A similar study performed by Kosiuk et al. confirmed our 
findings and showed a statistically non-significant trend 
toward reduced number of pocket hematomas with ID 
use compared to UW in patients receiving implantable 
devices (17). This study adds to the current body of 
literature suggesting this latter finding of reduced bleeding 
trends in ID group versus UW groups.
The primary goal in choosing an appropriate perioperative 
anticoagulation regimen is to prevent embolic events and 
reduce bleeding complications. Our results revealed no 
thromboembolic events in either group although this study 
was not powered to show differences in this outcome. 
One would expect that an uninterrupted anticoagulation 
strategy would reduce thromboembolic events better than 
an interrupted strategy, therefore favoring UW over ID. In 
our ID group, the mean time off dabigatran was 23.3 hours 
and the mean time to resume the dose was 21.0 hours 
post-procedure. One would expect most cardioembolic 
events would occur if anticoagulation were to be held 
for more than 48 hours. Since the half-life of dabigatran 
is 12-17 hours in patients with preserved renal function, 
one could postulate that withholding one or two doses of 
dabigatran would mean that a patient would remain not 
Table 3 Perioperative bleeding and thromboembolic complications*
Characteristic All patients [n=133] Uninterrupted warfarin [n=86] Interrupted dabigatran [n=47] P value
Major complication 0.8 [1] 1,2 [1] 0 [0] P>0.999
Major bleeding
Hemothorax 0 [0] 0 [0] 0 [0] P>0.999
Hemopericardium 0.8 [1] 1.2 [1] 0 [0] P>0.999
ICH 0 [0] 0 [0] 0 [0] P>0.999
GI Bleed 0 [0] 0 [0] 0 [0] P>0.999
Epistaxis req. packing 0 [0] 0 [0] 0 [0] P>0.999
Thromboembolic 
Stroke/TIA 0 [0] 0 [0] 0 [0] P>0.999
DVT 0 [0] 0 [0] 0 [0] P>0.999
PE 0 [0] 0 [0] 0 [0] P>0.999
Arterial embolism 0 [0] 0 [0] 0 [0] P>0.999
Minor complication# 4.5 [6] 7.0 [6] 0 [0] 0.09
Mortality
1 month mortality 0.8 [1] 1.2 [1] 0 [0] P>0.999
*, Perioperative time window was defined as 30 days post-implant; #, all pocket hematomas, all less than the size of the generator. 
DVT, deep venous thrombosis; GI, gastrointestinal; ICH, intracranial hemorrhage; PE, pulmonary embolism; TIA, transient ischemic 
attack.
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anticoagulated for less than the 48 hours window where the 
risk of clot formation is low and thus represent a reasonable 
perioperative bridging strategy.
It is still unknown whether uninterrupted dabigatran 
would be a viable option for patients undergoing implantable 
cardiac devices. The lack of a reversal agent makes this 
option less attractive and difficult to study. Perhaps in the 
future, once reversal agents become available, this strategy 
could be employed and formally studied in a large cohort 
study.
Our data support the use of ID as a reasonable strategy 
of treating patients undergoing cardiac device implantation. 
The results suggest that ID is at least as safe as continued 
warfarin in regards to bleeding. Though thromboembolic 
events were not different between the two groups, a large 
randomized trial powered to show those differences is 
needed. Survey data collected by Nascimento et al. has 
been useful in describing utilization and prescribing 
patterns of perioperative dabigatran use alongside other 
new oral anticoagulants among multiple centers in a 
large population (18). However, inter-center variability 
in anticoagulation stop and restart times limits accurate 
assessment of safety and efficacy outcomes. This highlights 
the need for a large randomized control trial to guide 
further therapy in this cohort of patients.
This study adds to the current literature regarding 
anticoagulation with dabigatran and can be utilized for 
future large-scale investigations.
Limitations
This study was not a randomized trial and therefore 
patients may have been prone to a selection bias, which 
likely accounted for the baseline CHADS2 score differences. 
Further, a relatively small sample size such as used in our 
study would be expected to show no difference in cardio-
embolic events due to lack of power. However, it is one of 
the largest studies available to date on this matter. It does 
support the fact that hematomas are not increased with 
the use of ID and may even be reduced compared to UW, 
which is consistent with findings from other studies (17).
Conclusions
This study suggests that ID and UW strategies are both 
reasonable approaches to managing patients requiring 
an ICD or a PPM. There was a trend towards lower 
pocket hematoma development in the ID group though 
this difference was not statistically significant. A large 
multicenter randomized trial is needed in order to 
definitively investigate any differences in thromboembolic 
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